ANTX
AN2 Therapeutics, Inc.
Price Chart
Latest Quote
$4.17
-0.03 (-0.71%)
Current Price
| Previous Close | $4.20 |
| Open | $4.27 |
| Day High | $4.45 |
| Day Low | $4.16 |
| Volume | 168,380 |
Stock Information
| Shares Outstanding | 36.02M |
| Cash Equivalents | $85.29M |
| Net Income | $-34.55M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $137.58M |
| EPS (TTM) | $-1.10 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $52.29M |
| Income | $-34.55M |
| Book/sh | $2.27 |
| Cash/sh | $2.37 |
| Employees | 21 |
Financial Ratios
| Quick Ratio | 15.33 |
| Current Ratio | 15.73 |
Returns & Margins
| ROA | -27.48% |
| ROE | -44.56% |
Ownership
| Insider Ownership | 19.00% |
| Institutional Ownership | 70.48% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -3.67 |
| P/B | 1.68 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $9.00 |
Technical Indicators
| SMA20 | $4.46 |
| SMA50 | $4.09 |
| SMA200 | $2.13 |
| RSI | 26.87 |
| ATR | 0.3873 |
| Shares Float | 17.02M |
| Short Float | 2.78% |
| Short Ratio | 2.87 |
| Rel Volume | 0.76 |
Performance History
| Week | -11.78% |
| Month | -17.85% |
| Quarter | +34.04% |
| 6 Months | +257.01% |
| YTD | +244.14% |
| Year | +250.46% |
| 3 Years | -31.91% |
| 10 Years | -75.19% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $3.82 | 178,200 |
| 2026-06-04 | $4.17 | 169,800 |
| 2026-06-03 | $4.20 | 214,500 |
| 2026-06-02 | $4.07 | 176,400 |
| 2026-06-01 | $4.21 | 236,200 |
| 2026-05-29 | $4.33 | 112,300 |
| 2026-05-28 | $4.46 | 191,900 |
| 2026-05-27 | $4.63 | 117,700 |
| 2026-05-26 | $4.73 | 535,800 |
| 2026-05-22 | $4.85 | 731,500 |
| 2026-05-21 | $4.89 | 102,400 |
| 2026-05-20 | $4.59 | 68,400 |
| 2026-05-19 | $4.55 | 83,600 |
| 2026-05-18 | $4.48 | 134,200 |
| 2026-05-15 | $4.75 | 408,700 |
| 2026-05-14 | $4.64 | 295,900 |
| 2026-05-13 | $4.31 | 263,400 |
| 2026-05-12 | $4.27 | 189,000 |
| 2026-05-11 | $4.72 | 213,700 |
| 2026-05-08 | $4.46 | 242,000 |
| 2026-05-07 | $4.60 | 149,300 |
| 2026-05-06 | $4.65 | 182,400 |
About AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize compounds and products, including epetraborole for the treatment, diagnosis, or prevention of various human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize compounds and products comprising epetraborole in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases; and GSK plc for the development of new therapies for TB. AN2 Therapeutics, Inc. was incorporated in 2017 and is headquartered in Menlo Park, California.
đ° Latest News
AN2 Therapeutics (ANTX) Upgraded to Buy: What Does It Mean for the Stock?
Zacks âĸ 2026-01-09T17:00:02Z
Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year?
Zacks âĸ 2026-01-09T14:40:02Z
Positive Signs As Multiple Insiders Buy AN2 Therapeutics Stock
Simply Wall St. âĸ 2025-06-28T13:39:51Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $38,109,000 | $54,554,000 | $69,635,000 | $42,262,000 |
| Other Income Expense | $1,000 | $-2,233,000 | $43,000 | $1,306,000 |
| Other Non Operating Income Expenses | $1,000 | $1,000 | $43,000 | $1,306,000 |
| Net Non Operating Interest Income Expense | $2,934,000 | $5,466,000 | $4,860,000 | $1,351,000 |
| Operating Expense | $38,109,000 | $54,554,000 | $69,635,000 | $42,262,000 |
| General And Administrative Expense | $13,340,000 | $14,066,000 | $14,764,000 | $12,751,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-35,174,000 | $-51,321,000 | $-64,732,000 | $-40,956,000 |
| Net Interest Income | $2,934,000 | $5,466,000 | $4,860,000 | $1,351,000 |
| Interest Income | $2,934,000 | $5,466,000 | $4,860,000 | $1,351,000 |
| Normalized Income | $-35,174,000 | $-49,087,000 | $-64,732,000 | $-40,956,000 |
| Net Income From Continuing And Discontinued Operation | $-35,174,000 | $-51,321,000 | $-64,732,000 | $-40,956,000 |
| Total Operating Income As Reported | $-38,109,000 | $-56,788,000 | $-69,635,000 | $-42,262,000 |
| Net Income Common Stockholders | $-35,174,000 | $-51,321,000 | $-64,732,000 | $-42,776,000 |
| Net Income | $-35,174,000 | $-51,321,000 | $-64,732,000 | $-40,956,000 |
| Net Income Including Noncontrolling Interests | $-35,174,000 | $-51,321,000 | $-64,732,000 | $-40,956,000 |
| Net Income Continuous Operations | $-35,174,000 | $-51,321,000 | $-64,732,000 | $-40,956,000 |
| Pretax Income | $-35,174,000 | $-51,321,000 | $-64,732,000 | $-40,956,000 |
| Special Income Charges | $0 | $-2,234,000 | $0 | - |
| Interest Income Non Operating | $2,934,000 | $5,466,000 | $4,860,000 | $1,351,000 |
| Operating Income | $-38,109,000 | $-54,554,000 | $-69,635,000 | $-42,262,000 |
| Per Share | ||||
| Diluted EPS | - | $-1.72 | $-2.74 | $-2.79 |
| Basic EPS | - | $-1.72 | $-2.74 | $-2.79 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-38,109,000 | $-52,320,000 | $-69,635,000 | $-42,262,000 |
| Total Unusual Items | $0 | $-2,234,000 | $0 | - |
| Total Unusual Items Excluding Goodwill | $0 | $-2,234,000 | $0 | - |
| EBITDA (Bullshit earnings) | $-38,109,000 | $-54,554,000 | $-69,635,000 | $-42,262,000 |
| EBIT | $-38,109,000 | $-54,554,000 | $-69,635,000 | $-42,262,000 |
| Diluted NI Availto Com Stockholders | $-35,174,000 | $-51,321,000 | $-64,732,000 | $-42,776,000 |
| Restructuring And Mergern Acquisition | $0 | $2,234,000 | $0 | - |
| Research And Development | $24,769,000 | $40,488,000 | $54,871,000 | $29,511,000 |
| Selling General And Administration | $13,340,000 | $14,066,000 | $14,764,000 | $12,751,000 |
| Other Gand A | $13,340,000 | $14,066,000 | $14,764,000 | $12,751,000 |
| Diluted Average Shares | - | $29,828,227 | $23,600,107 | $15,340,134 |
| Basic Average Shares | - | $29,828,227 | $23,600,107 | $15,340,134 |
| Preferred Stock Dividends | - | - | - | $1,820,000 |
| Otherunder Preferred Stock Dividend | - | - | - | - |
Fetched: 2026-06-02
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $53,060,000 | $81,849,000 | $124,701,000 | $95,372,000 |
| Total Assets | $61,950,000 | $92,087,000 | $138,744,000 | $102,560,000 |
| Total Non Current Assets | $2,013,000 | $5,825,000 | $28,237,000 | $3,939,000 |
| Investmentin Financial Assets | $2,013,000 | $5,021,000 | $27,194,000 | $3,219,000 |
| Current Assets | $59,937,000 | $86,262,000 | $110,507,000 | $98,621,000 |
| Other Current Assets | $1,936,000 | $2,644,000 | $3,212,000 | $2,562,000 |
| Cash Cash Equivalents And Short Term Investments | $58,001,000 | $83,618,000 | $107,295,000 | $96,059,000 |
| Cash And Cash Equivalents | $19,941,000 | $21,351,000 | $15,647,000 | $27,219,000 |
| Other Non Current Assets | - | $804,000 | $1,043,000 | $720,000 |
| Cash Equivalents | - | - | $4,478,000 | $10,152,000 |
| Cash Financial | - | - | $11,169,000 | $17,067,000 |
| Non Current Deferred Assets | - | - | - | $0 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | - | - | $0 | $53,000 |
| Current Debt And Capital Lease Obligation | - | - | - | $53,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $8,890,000 | $10,238,000 | $14,043,000 | $7,188,000 |
| Total Non Current Liabilities Net Minority Interest | $170,000 | $0 | $0 | $2,000 |
| Other Non Current Liabilities | $170,000 | - | - | - |
| Current Liabilities | $8,720,000 | $10,238,000 | $14,043,000 | $7,186,000 |
| Other Current Liabilities | $1,229,000 | $791,000 | $668,000 | $6,000 |
| Payables And Accrued Expenses | $5,073,000 | $7,771,000 | $9,357,000 | $4,959,000 |
| Payables | $3,021,000 | $3,317,000 | $2,676,000 | $2,122,000 |
| Accounts Payable | $3,021,000 | $3,317,000 | $2,676,000 | $2,122,000 |
| Derivative Product Liabilities | - | - | $0 | $2,000 |
| Equity | ||||
| Common Stock Equity | $53,060,000 | $81,849,000 | $124,701,000 | $95,372,000 |
| Total Equity Gross Minority Interest | $53,060,000 | $81,849,000 | $124,701,000 | $95,372,000 |
| Stockholders Equity | $53,060,000 | $81,849,000 | $124,701,000 | $95,372,000 |
| Gains Losses Not Affecting Retained Earnings | $57,000 | $31,000 | $275,000 | $-374,000 |
| Other Equity Adjustments | $57,000 | $31,000 | $275,000 | $-374,000 |
| Retained Earnings | $-240,950,000 | $-205,776,000 | $-154,455,000 | $-89,723,000 |
| Preferred Stock Equity | - | - | - | - |
| Preferred Securities Outside Stock Equity | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $27,413,171 | $29,919,634 | $29,741,445 | $19,402,658 |
| Share Issued | $27,413,171 | $29,919,634 | $29,741,445 | $19,402,658 |
| Tangible Book Value | $53,060,000 | $81,849,000 | $124,701,000 | $95,372,000 |
| Invested Capital | $53,060,000 | $81,849,000 | $124,701,000 | $95,372,000 |
| Working Capital | $51,217,000 | $76,024,000 | $96,464,000 | $91,435,000 |
| Total Capitalization | $53,060,000 | $81,849,000 | $124,701,000 | $95,372,000 |
| Additional Paid In Capital | $293,953,000 | $287,594,000 | $278,881,000 | $185,469,000 |
| Capital Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $2,418,000 | $1,676,000 | $4,018,000 | $2,168,000 |
| Current Accrued Expenses | $2,052,000 | $4,454,000 | $6,681,000 | $2,837,000 |
| Investments And Advances | $2,013,000 | $5,021,000 | $27,194,000 | $3,219,000 |
| Available For Sale Securities | $2,013,000 | $5,021,000 | $27,194,000 | $3,219,000 |
| Other Short Term Investments | $38,060,000 | $62,267,000 | $91,648,000 | $68,840,000 |
| Capital Lease Obligations | - | - | $0 | $53,000 |
| Current Capital Lease Obligation | - | - | $0 | $53,000 |
Fetched: 2026-06-02
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-29,834,000 | $-49,257,000 | $-53,288,000 | $-33,462,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-29,834,000 | $-49,257,000 | $-53,288,000 | $-33,462,000 |
| Cash Flow From Continuing Operating Activities | $-29,834,000 | $-49,257,000 | $-53,288,000 | $-33,462,000 |
| Investing Activities | ||||
| Investing Cash Flow | $28,311,000 | $54,589,000 | $-43,278,000 | $-21,771,000 |
| Cash Flow From Continuing Investing Activities | $28,311,000 | $54,589,000 | $-43,278,000 | $-21,771,000 |
| Financing Activities | ||||
| Financing Cash Flow | $113,000 | $372,000 | $84,994,000 | $70,355,000 |
| Cash Flow From Continuing Financing Activities | $113,000 | $372,000 | $84,994,000 | $70,355,000 |
| Issuance Of Capital Stock | - | $0 | $84,529,000 | $70,366,000 |
| Net Common Stock Issuance | - | $0 | $84,529,000 | $70,366,000 |
| Common Stock Issuance | - | $0 | $84,529,000 | $70,366,000 |
| Net Other Financing Charges | - | - | - | $-11,000 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| End Cash Position | $19,941,000 | $21,351,000 | $15,647,000 | $27,219,000 |
| Beginning Cash Position | $21,351,000 | $15,647,000 | $27,219,000 | $12,097,000 |
| Changes In Cash | $-1,410,000 | $5,704,000 | $-11,572,000 | $15,122,000 |
| Proceeds From Stock Option Exercised | $113,000 | $372,000 | $465,000 | $-11,000 |
| Net Investment Purchase And Sale | $28,311,000 | $54,589,000 | $-43,278,000 | $-21,771,000 |
| Sale Of Investment | $74,500,000 | $101,340,000 | $88,900,000 | $72,065,000 |
| Purchase Of Investment | $-46,189,000 | $-46,751,000 | $-132,178,000 | $-93,836,000 |
| Change In Working Capital | $164,000 | $-2,995,000 | $5,834,000 | $3,718,000 |
| Change In Other Current Liabilities | $608,000 | $126,000 | $613,000 | $-77,000 |
| Change In Payables And Accrued Expense | $-1,956,000 | $-3,928,000 | $6,247,000 | $5,473,000 |
| Change In Accrued Expense | $-1,660,000 | $-4,569,000 | $5,694,000 | $2,976,000 |
| Change In Payable | $-296,000 | $641,000 | $553,000 | $2,497,000 |
| Change In Account Payable | $-296,000 | $641,000 | $553,000 | $2,497,000 |
| Change In Prepaid Assets | $1,512,000 | $807,000 | $-1,026,000 | $-1,678,000 |
| Stock Based Compensation | $6,246,000 | $8,338,000 | $8,412,000 | $4,391,000 |
| Amortization Of Securities | $-1,070,000 | $-3,279,000 | $-2,855,000 | $-692,000 |
| Net Income From Continuing Operations | $-35,174,000 | $-51,321,000 | $-64,732,000 | $-40,956,000 |
| Other Non Cash Items | - | - | $53,000 | $77,000 |
| Change In Other Working Capital | - | - | - | $1,252,000 |
| Change In Other Current Assets | - | - | - | $-720,000 |
Fetched: 2026-06-02